NTRK fusion cancer is rare, affecting no more than a ... and is more common in sarcomas, brain, kidney and thyroid cancers. Use of the drug will depend on patients receiving genetic testing ...

Vitrakvi received full FDA approval for treating NTRK gene fusion-positive solid tumors in adults and children, following its initial accelerated approval in 2018. The drug functions as a tyrosine ...

Tumours with NTRK gene fusion produce an altered TRK protein ... cells and slow the worsening of the disease. TRK fusion cancer can occur in any part of the body, including the lungs, thyroid, colon, ...

Vitrakvi has demonstrated clinically meaningful and durable responses across various NTRK fusion-positive solid tumors. FDA first granted Vitrakvi accelerated approval in November 2018.

1 VITRAKVI has demonstrated clinically meaningful and durable responses across a range of NTRK fusion-positive solid tumors. VITRAKVI was first granted accelerated approval by FDA in November 2018.

sarcoma and thyroid cancers. Regulators in Japan are also reviewing Rozlytrek for ROS1 fusion-positive locally advanced or metastatic non-small cell lung cancer. Rozlytrek is under review by the ...

The firm submitted data from a registrational study showing the drug's activity in adult and adolescent patients with NTRK fusion-positive solid tumors.

"NTRK fusion-positive tumors represent a significant ... locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). It was approved by the FDA for this indication in November ...

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

VITRAKVI ® is now fully approved for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation ...